CVS replaces CEO Karen Lynch with Caremark head
Dive Brief: CVS Health on Thursday replaced CEO Karen Lynch as the healthcare and pharmacy giant’s financial challenges mount. CVS’ new...
Medicine
Gilead withdraws Trodelvy in bladder cancer
Dive Brief: Gilead will no longer sell its combination drug Trodelvy to treat bladder cancer, announcing Friday it had agreed...
Merck antibody reduces RSV-related disease, hospitalizations in trial
Dive Brief: An experimental antibody drug developed by Merck & Co. significantly reduced the incidence of disease due to respiratory...
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
Today, a brief rundown of news from PTC Therapeutics and Novartis, as well as updates from Amylyx Pharmaceuticals and Intercept...
Sage to cut one-third of workforce, streamline drug pipeline
Sage Therapeutics is restructuring yet again, announcing Thursday a company shakeup that will involve layoffs for about one-third of its...
Wave sees RNA editing validation in early trial results
Clinical trial results released by Wave Life Sciences Wednesday appear to provide early validation for the company’s newest drugmaking technology...
Novocure wins FDA approval for electric field device in lung cancer
Dive Brief: The Food and Drug Administration on Tuesday approved a new device to treat non-small cell lung cancer, Novocure’s...
Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss
Dive Brief: Sales of Johnson & Johnson’s cancer therapy Carvykti and immune disease drug Tremfya grew strongly during the third...
Forbion follows string of startup exits with $2.2B fundraise
Dive Brief: European life sciences venture firm Forbion on Tuesday said it has raised 2 billion euros, or more than...
As election day nears, Trump and Harris veer in different directions on pharma
With just a few weeks left until the election, Vice President Kamala Harris and former President Donald Trump are making...
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
The Food and Drug Administration has temporarily deflected a lawsuit alleging it violated federal law by removing Eli Lilly’s obesity...
Choosing the right hub partner: A blueprint for decision-makers
An effective launch sets the stage for a new drug’s long-term success. It shapes provider and patient perceptions, drives medication...
The number of AI medical devices has spiked in the past decade
The number of medical devices with artificial intelligence technology has risen sharply in the past decade. The Food and Drug...
Ex-Pfizer execs ‘threatened’ for supporting plans to shake up company, Starboard says
Two former Pfizer executives announced late Wednesday night that they won’t support efforts by activist investor Starboard Value to shake...
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody...
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
Today, a brief rundown of news from Roche and Turnstone Biologics, as well as updates from Sanofi, Pfizer and Flagship...
Sanofi may have found a buyer for its consumer health business
For the past year, French pharmaceutical giant Sanofi has been searching for a buyer to take control of its consumer...
UnitedHealth, CVS push to remove FTC Chair Lina Khan from PBM case
Dive Brief: UnitedHealth Group and CVS Health want Federal Trade Commission Chair Lina Khan and two other commissioners to recuse...
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody...
New data underline cancer risk of Bluebird therapy for brain disease
About two years ago, the Food and Drug Administration approved a personalized gene therapy for an ultra-rare childhood brain disorder...
Purespring raises $105M to advance gene therapy for kidney disease
Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the...
AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines
Basecamp Research, a biotechnology startup focused on artificial intelligence, has raised $60 million in funding and signed a multi-year collaboration...
Sage continues downslide as Alzheimer’s study fails
Alzheimer’s disease remains one of the world’s most indomitable illnesses, and on Tuesday it defeated yet another potential treatment in...
Scholar Rock scores with ‘surprise’ success in SMA drug study
Dive Brief: An experimental, muscle-preserving therapy from Scholar Rock succeeded in a Phase 3 trial in spinal muscular atrophy, positioning...
GSK’s ViiV to expand supply of HIV drug in Africa
Dive Brief: GSK-backed ViiV Healthcare on Monday said it plans to triple the amount of its HIV prevention therapy it...
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
Dive Brief: A new biotechnology company called Judo Bio is taking a strike at kidney diseases, armed with $100 million...
Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
Dive Brief: A major California health plan has struck a novel deal with a drug manufacturer for a cheaper version...
An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped?
Cassava Sciences has faced intense regulatory scrutiny over alleged clinical impropriety in studies of its experimental Alzheimer’s disease drug. Most...
Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Today, a brief rundown of news from Bristol Myers Squibb and Johnson & Johnson, as well as updates from Bayer,...
Sanofi’s rare disease drug finds yet another home
Over the past decade, the medicine Enjaymo has been passed around no less than five times by developers large and...
Editas trades Vertex fees for upfront cash in DRI deal
Dive Brief: Gene editing company Editas Medicines has sold off license fees and future payments it’s owed under an agreement...
FDA makes end of Zepbound, Mounjaro shortage official
Dive Brief: Shortages affecting the availability of Eli Lilly’s top-selling diabetes and weight-loss drugs have now been resolved, the Food...
Medicare tweaks rules for second round of drug price talks
The U.S. government is fine-tuning the rules for how it will negotiate drug prices within Medicare when the second round...
Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing
Dive Brief: Eli Lilly on Wednesday announced plans to spend $4.5 billion on a new facility that will use advancements...
Gilead agrees to license new HIV drug in low-income countries
Dive Brief: Gilead on Wednesday said it signed royalty-free licensing agreements with six generic drugmakers to produce and sell its...
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
Today, a brief rundown of news from IGM Biosciences and Metsera, as well as updates from Gritstone Bio, UCB and...
The top biopharma conferences in 2025
With rare exceptions, biotechnology and pharmaceutical companies validate their business plans through clinical trials, results from which are often presented...
Aktis raises $175M to fuel radiopharma drug development
Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. The...
Roche turns to a startup in search for new breast cancer drugs
Dive Brief: Roche on Monday agreed to pay $850 million to acquire two experimental breast cancer drugs being developed by...
Accelerating precision oncology: The value of an end-to-end partner for therapeutic access
Precision oncology continues to be one of the fastest-growing markets within pharmaceuticals. Valued at $130 Billion in 2023, the global...
Struggling 2Seventy scraps a key cancer study
2Seventy bio, the cancer-focused drugmaker spun out of Bluebird bio, has decided to stop enrolling a key study that’s been...
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science
Arch Venture Partners, a prominent creator of biotechnology startups, has raised more than $3 billion for its 13th fund, the...
Lawmakers call for investigation of former FDA device director
Dive Brief: Two House Democrats have called for an investigation of former Food and Drug Administration device director Jeff Shuren...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung...
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
Today, a brief rundown of news from J&J and the FDA, as well as updates from Sage Therapeutics, Roche and...
Bristol Myers schizophrenia drug, the first of its kind, approved by FDA
For the first time in more than two decades, a completely new form of antipsychotic medication will be available in...
Pfizer to pull sickle cell drug from market, shut down trials
Dive Brief: Pfizer is pulling the sickle cell disease drug Oxbryta off the market and ending clinical trials of the...
BioAge prices $198M IPO, validating pivot to obesity drug research
BioAge Labs has raised $198 million in an initial public offering, the company announced Wednesday, capitalizing on intense investor interest...
An Italian biotech gets $52M to advance pediatric gene therapies
Genespire, an Italy-based biotechnology startup making “off-the-shelf” gene therapies treatment for rare pediatric genetic conditions, has raised €46.6 million euros,...
Novo CEO pressed by Senate to cut prices of obesity, diabetes drugs
Novo Nordisk’s top executive vowed to reopen price negotiations with insurers covering the company’s obesity and diabetes drugs at a...
Bluebird to lay off another 25% of workforce in latest restructuring
Struggling gene therapy developer Bluebird bio is again cutting costs, announcing Tuesday a plan to lay off about a quarter...
Biogen, UCB get the lupus data they’ve waited two decades for
After more than two decades of work, partners Biogen and UCB say they finally have positive results from a late-stage...
AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble
Dive Brief: An experimental medicine from AstraZeneca and Daiichi Sankyo failed to help people with a common form of breast...
Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines
Dive Brief: Vicebio, a London-based biotechnology startup, has raised $100 million in Series B financing to continue developing a technology...
Startup from George Church’s lab raises $75M to develop ‘supercell’ medicines
A new company born out of research done by top Harvard genetic scientist George Church is promising to “revolutionize cell...
23andMe’s independent board directors resign
Dive Brief: 23andMe’s independent board directors resigned on Tuesday amid uncertainty about the DNA testing company’s future. In a letter...
Apellis eye drug again turned back in Europe
European drug regulators have officially turned back a first-of-its-kind eye drug from Apellis Pharmaceuticals despite multiple attempts by the company...
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
Today, a brief rundown of news from Sanofi and Novo Nordisk, as well as updates from The Lasker Foundation, Edgewise...
FTC sues major pharmacy benefit managers over insulin prices
Dive Brief: The Federal Trade Commission has filed suit against the three largest pharmacy benefit managers in the country for...
Roche’s Xofluza reduces flu transmission in Phase 3 study
Dive Brief: Roche’s antiviral drug Xofluza reduced influenza transmission among household contacts in a large Phase 3 study, the company...
4D Molecular data ‘bode well’ for eye gene therapy, but shares fall
Dive Brief: People with a common form of macular degeneration needed far fewer injections to manage their eye condition following...
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
Today, a brief rundown of news from Novartis and GSK, as well as updates from Omega Funds, Serán Bioscience and...
Ascendis trial data piles pressure on BioMarin
BioMarin Pharmaceutical, after months of layoffs, spending cuts and research reorganizations, has staked its future on the continued success of its...
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
Dive Brief: An antibody-drug conjugate developed by Daiichi Sankyo and Merck & Co. met the main goal of a Phase...
Sanofi readies to meet US demand for RSV antibody
Sanofi said it’s ready to meet demand for its RSV shot Beyfortus this year, announcing Monday the clearance by the...
ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapy’s survival impact
Over the weekend at the European Society for Medical Oncology’s annual meeting in Barcelona, cancer researchers unveiled results from scores...
Moderna to cut costs, trim pipeline in R&D revamp
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:...
Ten-year survival data show long-term benefit of immunotherapy in melanoma
A decade of follow-up on people with melanoma who were treated with cancer immunotherapy shows how two drugs have dramatically...
Gene therapy startup emerges with green light for first-of-its-kind trial
Vironexis Biotherapeutics emerged from stealth with plans to start what it claims will be the first-ever clinical trial testing a...
TIGIT drug from iTeos shrinks lung tumors in trial
Small biotechnology company iTeos Therapeutics could succeed where larger drugmakers have fallen short, should study results it presented Saturday at...
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
Today, a brief rundown of news from Roche and Gilead Sciences, as well as updates from Eli Lilly, Biogen and...
Moderna, trailing rivals, checks its RSV shot expectations
Months after winning approval of a new vaccine for respiratory syncytial virus, Moderna is acknowledging that wresting market share from...
Three biotechs raise $700M in rare burst of IPO activity
Three drug startups collectively raised more than $700 million in initial public offerings Thursday, a flurry of activity after a...
Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test
Dive Brief: An experimental drug Fulcrum Therapeutics has been testing against a type of muscular dystrophy failed a Phase 3...
Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound
Dive Brief: Sanofi and Regeneron plan to make a second attempt at expanding use of their blockbuster drug Dupixent to...
BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine
Dive Brief: BridgeBio Pharma plans to trim its spending on gene therapy research by more than $50 million after early-stage...
Investors are waking up to Centessa’s sleepiness drug
Early results from a small study have convinced Centessa Pharmaceuticals to “rapidly advance” an experimental drug it believes could be...
Bain closes $3B biotech fund amid flurry of startup buyouts
Bain Capital Life Sciences said Tuesday it has secured about $3 billion for its fourth fund, bringing the private investment...
Early study data puts Terns among obesity drug contenders
Dive Brief: An experimental weight loss pill developed by biotechnology company Terns Pharmaceuticals helped some people with obesity lose more...
Relay breast cancer drug shows potential in early trial
Dive Brief: An experimental drug regimen for breast cancer being developed by Relay Therapeutics delayed tumor growth by a median...
A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Nine years ago, Lisa Haines got news no one wants to hear. Her doctors said her lung cancer, which chemotherapy...
Summit lung cancer drug shows ‘striking’ benefit over Keytruda
An experimental medicine from a small biotechnology company cut the risk of lung cancer progression in half when tested against...
Novartis builds out radiopharma production with expansion, new factory
Dive Brief: Novartis said Wednesday it’s expanding a manufacturing site in Indianapolis and building a new plant in California in...
GSK antibody drug reduces COPD attacks in trial
Dive Brief: GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive...
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise
Today, a brief rundown of news from OrsoBio, as well as updates from Boehringer Ingelheim, Novartis and Vaxcyte that you...
Judge orders J&J to pay Auris investors more than $1B for merger violations
Dive Brief: A Delaware judge ruled Wednesday that Johnson & Johnson must pay Auris Health’s former investors more than $1...
Lykos CEO to depart after FDA rejection, layoffs
The CEO of Lykos Therapeutics will step down after the company’s efforts to win a milestone approval for MDMA as...
Lilly builds case for weekly insulin shot
Eli Lilly on Thursday revealed new data that could help it catch rival Novo Nordisk in a race between the...
BioMarin, having retrenched, outlines plans for growth
BioMarin Pharmaceutical has brought eight rare disease drugs to market over the past 25 years, a record few companies in...
High-dose Spinraza meets study goal; Top Dyne executives exit
Today, a brief rundown of news from Biogen, as well as updates from Dyne Therapeutics, Denali Therapeutics and Novo Nordisk...
Vaxcyte’s “best-case” data for pneumococcal vaccine boost shares
Dive Brief: Shares in vaccine developer Vaxcyte soared by over 35% Tuesday after the company unveiled results from a large...
New research could ease concerns over suicide risk of obesity drugs
Regulators in the U.S. and Europe recently determined that a popular group of drugs for weight loss and diabetes don't...
After an FDA rejection, here’s what’s next in the psychedelics pipeline
The psychedelic drug field hit a setback this month when the Food and Drug Administration rejected Lykos Therapeutics’ application for...
PBM executives threatened with fines for alleged perjury in House hearing
The chair of the powerful House Committee on Oversight and Accountability is threatening the leaders of the three largest pharmacy...
Cell and gene therapy investment, once booming, is now in a slump
Investment in developers of cell and gene therapies has nosedived this year, a sharp drop-off that investors and analysts say...
J&J submits touted autoimmune disease drug for FDA approval
Johnson & Johnson is asking the Food and Drug Administration to approve a new medicine the company believes can eventually...
Full study data back Alnylam heart drug’s benefit, but leave doctors with tough choices
Two months ago, Alnylam Pharmaceuticals revealed that a medicine it’s been developing for people with a deadly heart condition succeeded...
Novo builds heart failure case for semaglutide; Ventyx CFO departs
Today, a brief rundown of news from Novo Nordisk and Ventyx Biosciences, as well as updates from Novartis and Pfizer...
Keytruda fails lung and skin cancer trials, limiting further expansion
Dive Brief: Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the...
BioMarin to lay off over 200 employees
Amid a major corporate shakeout, BioMarin Pharmaceutical intends to lay off over 200 staff, according to a regulatory filing made...
Bayer partners with RNA drugmaker to develop new cancer therapies
Bayer and biotechnology company NextRNA Therapeutics on Wednesday said they have partnered to develop a new kind of small molecule...
Neurocrine’s mixed schizophrenia data disappoint Wall Street
Neurocrine Biosciences on Wednesday reported results from a schizophrenia drug study that, despite one bright spot, mostly disappointed investors. The...
Pfizer launches DTC service for migraine, COVID drugs
Pfizer on Tuesday launched a direct-to-consumer service it claims will help people schedule telehealth appointments, fill prescriptions and access savings...
Lilly rolls out Zepbound vials at a discount price
Dive Brief: Eli Lilly is now distributing a single-dose vial form of its popular weight loss medicine Zepbound that it...
Tome Biosciences to lay off over 100 employees
Genetic medicines startup Tome Biosciences is letting go of much of its staff after hitting setbacks following a buzzy launch...
Regeneron gains European approval for bispecific lymphoma drug
Dive Brief: The European Commission has authorized Regeneron’s dual-acting drug odronextamab to treat two types of lymphoma, clearing it for...
BioMarin taps Amgen, Roche vets in executive reshuffle
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. BioMarin is...
BridgeBio sends rare disease drugs to new company
BridgeBio Pharma has transferred several preclinical and early clinical-stage drugs to a new company, GondolaBio, that’s drawn $300 million in...
UK approves Leqembi, but reimbursement may not follow
Leqembi’s benefits are “too small to justify the significant cost to the NHS,” said the head of a UK agency...
FDA to convene immunotherapy panel; Tome scales back operations
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Today, a...
Two antibody startups file for IPOs amid summer slump
Dive Brief: A pair of U.S. biotechnology companies on Thursday filed plans for initial public offerings, testing a market that’s...
FDA defends med device chief’s tenure after report raises ethics concerns
The Food and Drug Administration is defending the record of Jeff Shuren, former director of the agency’s medical device center,...
Updated COVID shots from Pfizer, Moderna cleared by FDA
Dive Brief: The Food and Drug Administration on Thursday cleared new versions of Pfizer’s and Moderna’s COVID-19 vaccines that are...
Versant reimagines its Chinook success with newest startup launch
Chinook Therapeutics ranks among Versant Ventures’ most successful biotechnology bets. The kidney disease drug developer, which Versant founded in 2019...
Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues
Dive Brief: After warning investors earlier this month of a possible delay, Regeneron Pharmaceuticals on Tuesday confirmed that U.S. regulators...
Avidity, Kymera raise fresh funds; Walgreens partners with BARDA
Today, a brief rundown of stock sales by Avidity Biosciences and Kymera Therapeutics, as well as a new partnership between...
J&J drug combo for lung cancer approved by FDA
Dive Brief: The Food and Drug Administration has approved a new combination drug regimen from Johnson & Johnson to treat...
Novo plans new plant as it races to meet drug demand
A subsidiary of Danish drugmaker Novo Nordisk is investing 1.5 billion Danish kroner, or about $220 million, to build a...
FDA lifts partial hold on study of BioNTech-partnered ADC
BioNTech partner MediLink Therapeutics can resume enrollment of a Phase 1 clinical trial testing an antibody-drug conjugate in people with...
Evotec, citing research spending slowdown, cuts jobs and exits gene therapy
Dive Brief: Evotec, a German drug discovery and contract development and manufacturing company, is restructuring amid a slowdown in early-stage...
FDA clears Gilead drug acquired in $4.3B buyout
Dive Brief: Gilead Sciences has won Food and Drug Administration approval to sell Livdelzi, a new medicine for a rare...
Incyte builds out its arsenal of post-transplant drugs
The Food and Drug Administration has approved another medicine for a rare condition that arises after a bone marrow or...
Medicare drug price cuts could have limited early impact, but grow with time
The Biden administration struck a triumphant tone on Thursday in rolling out the first drug price cuts negotiated by Medicare,...
Pfizer, BioNTech stumble in effort to develop combination flu, COVID shot
Dive Brief: Pfizer and BioNTech on Friday said a combination flu and COVID-19 shot they’ve been developing met one of...
Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance
Today, a brief rundown of news from Zealand Pharma and Bluebird Bio, as well as updates from Boundless Bio and...
Lykos to cut 75% of staff after FDA rejection of MDMA-based therapy
Lykos Therapeutics plans to lay off about 75% of its staff as part of a larger shake-up at the California-based...
Medicare reveals results of drug price negotiations
The U.S. government on Thursday said it stands to save taxpayers $6 billion on the prices it will pay for...
Grail to shed 350 workers in restructuring
Dive Brief: Grail said it will lay off about 350 employees in a restructuring that comes less than two months...
Pfizer appoints AI chief, expanding digital leadership team
Dive Brief: Pfizer has added Berta Rodriguez-Hervas as its chief AI and analytics officer, the pharmaceutical company confirmed to CIO...
Acelyrin shifts from main drug, lays off staff
Dive Brief: Acelyrin, the biotechnology company behind the sector’s largest initial public offering last year, is shifting away from the...
Pfizer builds case for RSV shot with data from immunocompromised adults
Dive Brief: Pfizer on Monday said its RSV vaccine Abrysvo led to strong immune responses in immunocompromised adults given the...
Following FDA rejection, a journal retracts papers on MDMA-assisted therapy
A day after the Food and Drug Administration rejected MDMA as a therapy aid for post-traumatic stress disorder, a scientific...
Lilly boosts outlook on rising Zepbound revenue
Dive Brief: Eli Lilly on Tuesday raised its revenue forecast for the year by $3 billion as it reported second-quarter...
Recursion to absorb Exscientia in ‘techbio’ deal
Dive Brief: Recursion and Exscientia, two artificial intelligence firms, on Thursday announced that they would combine, betting their complementary skills...
Apellis plans FDA filing after drug success in kidney trial
Dive Brief: Treatment with an Apellis Pharmaceuticals drug appeared to benefit people with one of two uncommon kidney diseases, according...
Zepbound shortages ease, but Lilly cautions pharmacy availability may remain ‘choppy’
Eli Lilly is making progress resolving the supply strains that for months have made its in-demand obesity and diabetes medicines...
Merck bets $700M on an antibody drug’s potential in immune diseases
Merck & Co. on Friday acquired an experimental drug designed to wipe out the immune system’s B cells in a...
In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD
The Food and Drug Administration has rejected a bid to get MDMA approved as a therapy aid for people with...
With pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
The recent downturn in the biotechnology sector affected startups in many ways, from the availability of financing to the types...
Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study
Today, a brief rundown of news from Merck & Co. and Cabaletta Bio, as well as updates from Intellia Therapeutics,...
Novo shares tumble on lower-than-expected obesity drug sales
Dive Brief: Novo Nordisk shares tumbled 7% in early trading Wednesday after the company reported lower-than-expected revenue from its blockbuster...
Amgen talks obesity drug ‘differentiation’; Servier brain cancer drug approved by FDA
Today, a brief rundown of news from Amgen and Servier, as well as updates from Merck & Co., Precigen and...
Biotech entrepreneur Arie Belldegrun launches new ‘science-first’ credit firm
Dive Brief: Arie Belldegrun, the founder of Allogene Therapeutics and Kite Pharma, unveiled a new credit firm Tuesday with $600...
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Despite decades of research and many millions of dollars invested, Roche still has yet to develop a drug that works...
Biotech Red Queen launches with $55M to build versatile antivirals
Venture firm Apple Tree Partners has invested $55 million in a new biotechnology company developing antiviral treatments capable of working...
Zepbound, Mounjaro back in supply as Lilly resolves shortage
Dive Brief: All doses of tirzepatide, the drug Eli Lilly sells as Zepbound for obesity and Mounjaro for diabetes, are...
Why pharma should invest in evidence-based physician education
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first...
Cigna CEO promises ‘aggressive’ defense of pharmacy benefit managers
Dive Brief: Cigna’s chief executive is pledging to be more aggressive in defending its pharmacy benefit manager amid mounting public...
Moderna shares fall amid lower sales outlook for RSV, COVID shots
Shares of Moderna fell nearly 20% on Thursday after the company lowered its 2024 financial forecasts amid slowing sales and...
Lilly obesity drug shows heart benefit in late-stage trial
Eli Lilly’s tirzepatide, the in-demand drug sold as Zepbound for weight loss, has for the first time been shown in...
Vir retreats from infectious disease; Vertex shelves AATD drugs
Today, a brief rundown of news from Vir Biotechnology and Vertex Pharmaceuticals, as well as updates from Neurocrine Biosciences, Alnylam...
First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer
The Food and Drug Administration on Thursday approved a new type of cellular medicine, clearing a therapy developed by the...
Jim Wilson, prominent gene therapy researcher, to depart UPenn
Prominent gene therapy researcher Jim Wilson will depart the University of Pennsylvania, where he led one of the field’s largest...
UniQure restructuring to claim 300 jobs
Dive Brief: Gene therapy developer UniQure will shrink its workforce by 65%, cutting 300 roles across the company alongside the...
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
Today, a brief rundown of news from Vertex Pharmaceuticals and Merck & Co. as well as updates from Fibrogen, Intellia...
GSK cuts vaccine forecasts, while predicting faster overall growth
Dive Brief: GSK on Wednesday lowered its forecast for vaccine sales this year, citing inventory changes and shifting retail prioritization...
Biotech startup Airna raises $60M for RNA editing medicines
Dive Brief: RNA editing startup Airna is adding more funds to its Series A round, raising another $60 million as...
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
Pfizer missed its first chance at following Novo Nordisk and Eli Lilly into the fast-growing market for GLP-1 obesity drugs....
GSK leans on Flagship for help finding new drugs, vaccines
Dive Brief: GSK is the latest pharmaceutical company to form a drug-hunting partnership with Flagship Pioneering, announcing Monday a deal...
How a Mubadala partner views investing in biotech’s new normal
After a dramatic post-pandemic downturn, a sense of stabilization has returned to biotech, and more healthcare professionals feel optimistic about...
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
Today, a brief rundown of news from Dren Bio and Geron as well as updates from Moderna, Brenig Therapeutics and...
Viking shares jump on plans to speed obesity drug into late-stage testing
Viking Therapeutics shares soared by more than 30% early Thursday after the company told investors it’s moving an experimental obesity...
Warren, Democratic lawmakers introduce bill to resurrect Chevron doctrine
Dive Brief: Sen. Elizabeth Warren, D-Mass., introduced legislation that would reverse the Supreme Court’s recent ruling on the Chevron doctrine,...
Leqembi voted down by European regulators
A key regulatory committee that influences whether new drugs enter the European market has voted against Leqembi, Eisai and Biogen’s...
Two biotechs cut staff; AbbVie weathers biosimilar threat
Today, a brief rundown of news from AbbVie and AstraZeneca as well as updates from Glycomimetics, Cue Biopharma and Confo...
Bristol Myers’ beat completes strong week of pharma earnings
Bristol Myers Squibb on Friday raised its forecast for revenue and profit per share this year after a second quarter...
Sanofi’s immunology bet starts to pay off
Shares of French pharmaceutical giant Sanofi ticked up Thursday morning with the release of an earnings report that beat Wall...
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
Roche is best known for the cancer drugs that still account for much of its drug revenue. But the Swiss...
Pfizer says hemophilia gene therapy meets late-stage study goal
Dive Brief: An experimental gene therapy from Pfizer succeeded in a Phase 3 study of people with hemophilia A, overcoming...
Biogen, Sage tremor drug fails key trial
In 2020, Biogen wagered more than $1 billion on two experimental drugs developed in the labs of Sage Therapeutics, a...
Merck claims late-stage study success for RSV antibody
Dive Brief: An experimental Merck & Co. drug designed to protect infants from illness caused by respiratory syncytial virus succeeded...
Ionis plots next steps for Angelman drug Biogen passed on
Ionis Pharmaceuticals plans to push one of its rare disease drugs into late-stage testing now that a smaller trial has...
US government declines to clear Bluebird fertility support for Zynteglo patients
The U.S. government will not give Bluebird bio a green light to offer fertility support to federally insured people undergoing...
Breakthroughs in immunotherapy: glycoproteins as predictive biomarkers for therapeutic response
Recent advancements in immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA4 have shown significant success in treating various advanced cancers...
Gilead’s CMO to depart next year
Dive Brief: Gilead chief medical officer Merdad Parsey will step down from his role and leave the biotechnology company early...
Caribou lays off staff; Roche walks away from Relay
Today, a brief rundown of news from Caribou Sciences and Relay Therapeutics as well as updates from Corden Pharma, Celldex...
Obesity pill from Roche shows promising weight loss in small study
Dive Brief: A closely watched obesity pill being developed by Roche helped people in a small Phase 1 trial lose...
Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
Today, a brief rundown of news from Morphic Holding as well as updates from Novartis, the Parker Institute and Agenus...
Global tech outage hits US hospitals
Cybersecurity firm CrowdStrike triggered a massive IT outage on Friday, disrupting businesses, including healthcare, after issuing what was supposed to be a...
Artiva prices $167M IPO, riding optimism for autoimmune cell therapy
Dive Brief: Artiva Biotherapeutics on Thursday raised $167 million in an initial public offering centered around the promise of donor-derived cell...
Boehringer cuts price of Humira biosimilar in bid to build use
Boehringer Ingelheim will sell an unbranded version of its Humira biosimilar at a 92% discount to the list price of...
In strengthening Spravato sales, a positive sign for psychedelic drugs
Dive Brief: Sales of Johnson & Johnson’s depression drug Spravato accelerated in the second quarter, putting the medicine on pace...
Medical device firms have cut more than 14,000 jobs in the past 18 months
Medical device companies have been steadily cutting jobs for the past 18 months, eliminating thousands of positions as firms look...
Vertex taps Orum to hunt for better ‘preconditioning’ drugs
Vertex Pharmaceuticals is exploring new ways to prepare patients for intensive therapies like its sickle cell treatment Casgevy, announcing Tuesday...
Cardurion raises another $260M to fuel heart drug pipeline
Dive Brief: Biotechnology startup Cardurion Pharmaceuticals on Tuesday raised a $260 million Series B round that will help it build...
Asceneuron raises another $100M for Alzheimer’s drug development
Asceneuron, a Switzerland-based biotechnology company, has raised another $100 million to support its work developing drugs that target a protein...
Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
Dive Brief: An experimental cancer drug developed by Revolution Medicines shrank pancreatic tumors in about one-quarter of participants who had...
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
Amylyx Pharmaceuticals achieved what all upstart drugmakers hope to accomplish. In less than 10 years, the Massachusetts-based biotechnology company identified...
As GLP-1 drugs boom, other healthcare companies are cashing in
The popularity of new GLP-1 drugs for weight loss is giving rise to a secondary market with large revenue potential,...
Flagship raises $3.6B for biotech investing
Dive Brief: Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised...
FDA’s lab-developed test rule could be first test of agency’s power post-Chevron
The recent U.S. Supreme Court decision to overturn the Chevron doctrine could open the door to more challenges of Food...
Bristol Myers’ leukemia blockbuster set to face generic rivals
Pharmaceutical companies face a looming patent cliff over the next several years, as generic rivals could erode sales of some...
Leqembi sales inch higher; Spark’s pivot leads to layoffs
Today, a brief rundown of news from Eisai, Spark Therapeutics and Ipsen as well as updates from Element Biosciences and...
Novo’s once-weekly insulin rejected by FDA
Dive Brief: The Food and Drug Administration rejected Novo Nordisk’s application to sell a once-weekly insulin treatment called icodec, sending...
Pfizer thinks it found its obesity pill
With tens of billions of dollars at stake, some of the world’s largest drug companies are racing to develop pills...
FTC to sue three largest PBMs over drug price practices: WSJ
Dive Brief: The Federal Trade Commission is preparing to sue the three largest pharmacy benefit managers in the U.S. —...
AbbVie names new R&D head; Arcutis eczema cream approved
Today, a brief rundown of news from AbbVie and Skyhawk Therapeutics, as well as updates from Arcutis Biotherapeutics and Zevra...
SciRhom pulls in $70M for a new type of immune disease drug
SciRhom, a German biotechnology startup focused on autoimmune diseases, has raised a $70 million Series A funding round that will...
FTC criticizes PBM power over prescription drug market
The Federal Trade Commission on Tuesday released a long-awaited report criticizing the pharmacy benefit manager industry for manipulating the drug...
HilleVax’s norovirus vaccine ineffective in large trial of infants
Dive Brief: Biotechnology company HilleVax on Monday said it will halt development of an experimental norovirus vaccine in infants after...
